Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
The company’s CD38 x CD28 MAb is among recent clinical trial entrants.
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
The company defends its cancer strategy, and says it's not a me-too developer.
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
Eagerly awaited data with the anti-PD-L1 x 4-1BB bispecific acasunlimab raise liver toxicity concerns.
Lilly’s Mablink acquisition challenges Genmab’s move for ProfoundBio.